G
GeneDx Inc
Biotech & Life Sciences · Gaithersburg, United States · Founded 2000 · IPO 2020
Delivering personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery MoreLess
GeneDx is a pioneering company in the field of clinical genomics and rare disease diagnostics. The company specializes in genetic testing, which involves analyzing a patient's DNA to identify changes or mutations that could be linked to various health conditions. GeneDx serves a diverse range of clients, including patients, families, and healthcare providers, who rely on its expertise to gain deeper insights into genetic disorders.
Operating in the healthcare and biotechnology market, GeneDx has established itself as a leader by sequencing more than 300,000 clinical patient exomes. An exome is the part of the genome that contains genes, which are crucial for understanding genetic diseases. The company uses advanced techniques to collect DNA samples from cheek swabs, blood, or other specimens. These samples are then sequenced to detect genetic variations. The results are analyzed by a team of technical and clinical experts, and a detailed report is sent back to the healthcare provider.
GeneDx's business model revolves around providing rapid and accurate genetic testing services. They offer products like GenomeXpress and XomeDx Xpress, which deliver results in as little as seven days. This quick turnaround is vital for critical cases where timely diagnosis can significantly impact treatment outcomes, reduce hospital stays, and lower healthcare costs.
The company generates revenue by charging for its genetic testing services. Healthcare providers, hospitals, and clinics pay for these tests to diagnose and manage genetic conditions in their patients. Additionally, GeneDx offers digital Patient Letters, which provide personalized genetic information to patients and their families, enhancing their understanding of the test results.
In summary, GeneDx is at the forefront of clinical genomics, offering rapid and reliable genetic testing services that cater to patients, families, and healthcare providers. Their innovative approach and deep clinical expertise make them a key player in the personalized medicine landscape.
Keywords: Clinical Genomics, Genetic Testing, Rare Diseases, DNA Sequencing, Healthcare Providers, Rapid Diagnosis, Personalized Medicine, Exome Sequencing, Genetic Variations, Patient Letters.
Company overview
GeneDx Inc company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2000
- Headquarters
- Gaithersburg, United States
- Employees
- 1,261
- Open positions
- 29
- Dealroom signal
- 94.9
- Investment activity
- 1 companies · latest May 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
GeneDx Inc funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $43M | — | Prosight Management | ↗ |
| DEBTDebt | Mar 2026 | $100M | — | Undisclosed | ↗ |
| GROWTH EQUITY VCOther financing | Nov 2025 | $100M | — | Undisclosed | ↗ |
| DEBTDebt | Oct 2023 | $75M | — | Perceptive Advisors | ↗ |
| ACQUISITIONOther financing | Jan 2022 | $623M | $623M | Sema4 | ↗ |
| SPAC PRIVATE PLACEMENTOther financing | Jul 2021 | Perceptive Advisors | — | ||
| SPAC PRIVATE PLACEMENTOther financing | Jul 2021 | Perceptive Advisors | — | ||
| IPOOther financing | Nov 2020 | Undisclosed | — | ||
| SPINOUTOther financing | Jan 2000 | National Institutes of Health | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $428M | 0% | $13M | 3.1% |
| 2025 | $428M | +40% | $13M | 3.1% |
| 2024 | $305M | +50.8% | $12M | 4% |
| 2023 | $203M | -13.7% | −$127M | -62.8% |
| 2022 | $235M | +10.6% | −$396M | -168.6% |
| 2021 | $212M | +18.3% | −$424M | -200% |
| 2020 | $179M | — | −$227M | -126.7% |
Growth signals
GeneDx Inc website traffic
Latest recorded traffic for GeneDx Inc is 79K monthly website visits, up 23.4% over the last three months. GeneDx Inc's team grew 51.2% over the past year.
Hiring
Open positions at GeneDx Inc
Current openings linked to this company in Dealroom.
Comparisons
GeneDx Inc compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
GeneDx Inc investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
GeneDx Inc's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where GeneDx Inc has talent and traffic
team presence
In the news
Latest news about GeneDx Inc
Recent press, funding announcements, and product moves mentioning GeneDx Inc — open to read from the original sources.
Market sentiment
What the market is saying about GeneDx Inc
An AI-synthesized read of the highest-engagement posts about GeneDx Inc on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneDx Inc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











